Literature DB >> 8885114

Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.

T W May1, B Rambeck, U Jürgens.   

Abstract

Lamotrigine (LTG) is a new antiepileptic drug (AED), chemically unrelated to the drugs in current use. Previous studies have shown that LTG has only a limited effect on other AEDs, but its own metabolism can be strongly induced or inhibited by the comedication. We investigated the influences of carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), valproic acid (VPA), and combinations of these drugs on the serum concentration of LTG. A total of 588 blood samples from 302 patients were analyzed. The mean duration of LTG therapy was 141 +/- 137 days (mean +/- SD). A patient was only considered twice in this study if his or her comedication had been changed. The LTG serum concentration in relation to LTG dose/body weight (level-to-dose ratio, LDR, microgram/ml/mg/kg) was calculated and compared for different drug combinations. The results showed that comedication had a highly significant (p < 0.001) influence on the LTG serum concentrations. The mean LDR for LTG was 0.32 (LTG + PHT) < 0.52 (LTG + PB) approximately equal to 0.57 (LTG + CBZ) < 0.98 (LTG mono) approximately equal to 0.99 (LTG + VPA + PHT) < 1.67 (LTG + VPA + CBZ) approximately equal to 1.80 (LTG + VPA + PB) < 3.57 (LTG + VPA (<, p < 0.05; approximately equal to, p > 0.05, multiple comparisons). The mean LTG concentrations in patients on comedication with VPA were about two times higher than on patients on LTG monotherapy or on comedication without VPA (5.0 vs. 2.6 micrograms/ml), despite the LTG doses being half as high (3.0 vs. 5.9 mg/kg). The correlations of the serum concentrations and doses of CBZ, PB, PHT, and VPA with the LDR of LTG were only weak or not significant. Furthermore, the distribution of LTG serum concentrations and dosages was compared with the tentative therapeutic range for the LTG concentration (1-4 micrograms/ml), proposed by some investigators, and the recommendations for the LTG dosage. Remarkable discrepancies were observed. The comedication has an important influence on the LTG concentration and should be considered in LTG dosage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885114     DOI: 10.1097/00007691-199610000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

1.  Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.

Authors:  A M Almeida; A C Falcão; F Sales; I Baldeiras; M J Rocha; M M Caramona
Journal:  Eur J Clin Pharmacol       Date:  2006-07-27       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

3.  A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.

Authors:  Todd M Conner; Ronald C Reed; Tao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 4.  The tolerability of lamotrigine in children.

Authors:  J A Messenheimer; L Giorgi; M E Risner
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 5.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

Review 6.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

7.  Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.

Authors:  Mladena Lalic; Jelena Cvejic; Jovan Popovic; Ksenija Bozic; Svetlana Golocorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

8.  Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Authors:  Kazuyuki Inoue; Yoshiaki Yamamoto; Eri Suzuki; Toshiki Takahashi; Akiko Umemura; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

9.  Lamotrigine in multihandicapped therapy-resistant epileptic patients.

Authors:  B Huber; T May; M Seidel
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 10.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.